Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Pharmacia & Upjohn submits applications for once-daily Detrol formulation

March 10, 2000

New 5alpha-reductase inhibitors in the pipeline at Kotobuki

March 8, 2000

Merck returns alpha-adrenergic technology rights to Synaptic

March 7, 2000

C5 inhibitor from Alexion granted fast track status for kidney disease

March 2, 2000

Dosing begins in phase II trial of Alprox-TD for erectile dysfunction

Feb. 28, 2000

Nastech's intranasal apomorphine compared to Viagra in phase II pilot trial

Feb. 25, 2000

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Feb. 24, 2000

Potent and selective alpha1D-adrenoceptor antagonists presented by Abbott

Feb. 18, 2000

Cortex receives notice of allowance for sexual dysfunction patent

Feb. 16, 2000

Preclinical studies support potential new indication for tamsulosin

Feb. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.